KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
105 hedge funds and large institutions have $408M invested in KalVista Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 20 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 33
3.93% less ownership
Funds ownership: 99.59% → 95.67% (-3.9%)
5% less funds holding
Funds holding: 110 → 105 (-5)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
28% less capital invested
Capital invested by funds: $567M → $408M (-$159M)
85% less call options, than puts
Call options by funds: $533K | Put options by funds: $3.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$7.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.51M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$3.18M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.61M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$8.79M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.23M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$5.47M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.49M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.95M |
KALV Hedge Fund Activity: Q3 2021 in Review
105 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2021, worth a combined $408M — down 28% from $567M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KALV and 16 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 34 added.
The largest buyer was Suvretta Capital Management, adding an estimated $7.14M. The largest seller was Nicholas Investment Partners, cutting an estimated $8.79M.
- 105 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2021, down from 110 in Q2 2021.
- Funds reported $408M of KalVista Pharmaceuticals stock for Q3 2021, down 28% quarter-over-quarter.
- 16 funds opened new KalVista Pharmaceuticals positions in Q3 2021 and 20 closed out, a net change of -4 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2021 was Suvretta Capital Management, an estimated $7.14M added.
- The largest KalVista Pharmaceuticals seller in Q3 2021 was Nicholas Investment Partners, an estimated $8.79M sold.
Based on aggregated 13F filings for Q3 2021.